Elad Sintov, United States

Elad Sintov completed his BSc in biotechnology engineering at Ben-Gurion University, Israel. In his PhD he studied adult human beta-cell-derived cell redifferentiation after expansion ex-vivo. As a post-doctoral fellow in Doug Melton's lab, Elad worked on ways to model autoimmunity in vitro, and using CRISPR screens and single cell transcriptomic, gain insights that could allow for preventing/evading the allo-rejection response against stem-cell derived islets for the treatment of type-1 diabetes. In 2022, Elad started as a Stem cell research Senior Scientist in Vertex Pharmaceuticals Inc.